By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Callisto Pharmaceuticals 

420 Lexington Avenue, Suite 1609

New York  New York  10170  U.S.A.
Phone: 212-297-0010 Fax: 212-297-0020




Company News
Synergy Pharmaceuticals Announces Closing of Merger With Callisto Pharmaceuticals 1/18/2013 9:16:36 AM
Callisto Pharmaceuticals Stockholders Approve Merger With Synergy Pharmaceuticals 1/15/2013 9:19:08 AM
Synergy Pharmaceuticals Signs Definitive Agreement to Acquire Callisto Pharmaceuticals 7/23/2012 9:50:56 AM
Callisto Pharmaceuticals Adjourns Annual Stockholders Meeting Due to Lack of a Quorum 7/12/2010 9:32:21 AM
Callisto Pharmaceuticals Redirects Atiprimod Clinical Development to Treat Rheumatoid Arthritis 1/27/2009 9:52:31 AM
Callisto Pharmaceuticals’ Majority-Owned Subsidiary Synergy Pharmaceuticals Completes Phase I Trial of SP-304 in Volunteers 12/9/2008 1:23:38 PM
Callisto Pharmaceuticals Announces $3.0 Million Financing by Its Synergy Pharmaceuticals Subsidiary and Related Transactions Leaving Callisto with a 68% Stake in Synergy 7/21/2008 11:08:20 AM
Callisto Pharmaceuticals Opens Phase I Clinical Trial of SP-304 to Treat Chronic Constipation and Irritable Bowel Syndrome 6/4/2008 10:12:57 AM
Callisto Pharmaceuticals Reports Promising Interim Phase II Data for Atiprimod in Advanced Carcinoid Cancer 5/16/2008 8:57:28 AM
Callisto Pharmaceuticals Receives Notice of Delisting From AMEX - Subject to Appeal 4/14/2008 9:26:24 AM